Analysts are offering a measured outlook on several prominent healthcare companies, including Astrana Health (ASTH), Becton Dickinson (BDX), and United Therapeutics (UTHR). Their neutral ratings suggest a balanced perspective, with neither strong optimism nor pessimism regarding these stocks.
Astrana Health Overview
Matthew Gillmor, a CFA from KeyBanc, recently maintained a Hold rating on Astrana Health. The stock’s performance has seen it close at $26.32, alarmingly near its 52-week low of $23.12. Despite this, the general consensus among analysts leans toward a Strong Buy, with an average price target set at $35.00, indicating a potential upside of 45.6% from current levels.
Gillmor’s track record on TipRanks shows a 1-star rating, with an average return of -1.4% and a success rate of 47.4%. His focus within the healthcare sector includes companies like BrightSpring Health Services and Alignment Healthcare, though his cautious stance on Astrana is noteworthy.
Becton Dickinson Insights
Turning to Becton Dickinson, Travis Steed from Bank of America Securities has also assigned a Hold rating, projecting a price target of $221.00. The stock’s recent closing price was $176.54, leaving room for potential growth.
Steed is considered a 4-star analyst, showcasing an average return of 4.8% and a success rate of 56.4%. He covers various healthcare entities, including GE Healthcare Technologies and Bausch + Lomb Corporation. The analyst consensus for Becton Dickinson reflects a Moderate Buy, with a target price of $191.20, suggesting a 9.8% upside.
United Therapeutics Analysis
Jason Gerberry, another analyst from Bank of America Securities, reiterated a Hold rating on United Therapeutics, setting a price target of $569.00. The stock recently closed at $513.82, indicating potential for slight growth.
Gerberry enjoys a solid reputation as a 5-star analyst, with an impressive average return of 17.9% and a success rate of 63.6%. His coverage includes companies like Harmony Biosciences and Amylyx Pharmaceuticals. The consensus on United Therapeutics stands at a Moderate Buy, with an average price target of $528.70, which represents a modest upside of 3.8%.
Market Sentiment
The overall sentiment in the healthcare sector, as articulated by these analysts, highlights a cautious yet optimistic view. While the ratings remain neutral, the potential for price appreciation in each of these stocks cannot be overlooked.
Analysts are keenly observing market movements and the underlying fundamentals of these companies, which may provide further clarity in the future. Their insights serve as valuable guidance for investors looking to navigate the complex landscape of healthcare investments.
Key Takeaways
- Astrana Health is currently rated as a Hold by analysts, with a substantial upside projected based on an average price target of $35.00.
- Becton Dickinson holds a Moderate Buy consensus, with a price target suggesting a nearly 10% upside from its current price.
-
United Therapeutics also demonstrates potential growth, albeit modest, with an average price target of $528.70.
In conclusion, the current analyst evaluations of Astrana Health, Becton Dickinson, and United Therapeutics reflect a landscape where cautious optimism prevails. Investors should consider these insights as part of a broader strategy, weighing potential gains against the inherent risks of the healthcare sector. The balance of ratings suggests that while opportunities exist, vigilance is key in this ever-evolving market.
Read more → www.theglobeandmail.com